New Cancer Vaccines Offers Hope to Millions
Highly promising new cancer vaccines due to land over the next few years could change the lives of cancer patients around the world, predicts a report by healthcare business analysts GlobalData.
The report* explains that the current unmet need in the cancer vaccines industry may be fulfilled by a range of treatments in different stages of clinical trials, including some considered first-in-class.
The cancer vaccine market comprises of the prophylactic and the therapeutic sectors, and while there are interesting developments expected in both, it is the latter that offers the most inspiring innovations.
The therapeutic vaccine market is extremely under-populated at present, with only one product available: Provenge, a dendritic cell vaccine for the treatment of advanced prostate cancer that is currently only available in the US.
But GlobalData predicts this to change significantly over the next six years with the introduction of a series of first-in-class treatments with exciting tolerability and safety profiles. These vaccines include Allovectin-7 and OncoVEX, for the treatment of Melanoma, BiovaxId (Idiotype vaccine therapy) for follicular non-Hodgkin lymphoma, and GV1001 for advanced pancreatic cancer.
Many therapies used today to help patients suffering from these cancers have side-effects ranging from high toxicity, to short-term or unpredictable efficacy. There is hope among the medical community that innovations made in the cancer vaccine industry can address these problems and perhaps even change the landscape of future cancer treatments.
Cancer vaccines are a particularly exciting development as they can be used in conjuction with treatments such as chemotherapy, radiation and surgery. A myriad of pharmaceutical companies, including Vical, Biovest International, NewLink Genetics Corporation and NovaRx Corporation, are making cancer vaccines an area of focus, and we can therefore expect to see these firms among the big figures in the market in the years to come.
This report is an essential source of information and analysis on the global cancer vaccines market. It identifies the key trends shaping and driving the global cancer vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
Written by Kevin McHugh